Is a Longer Schedule of Decitabine More Effective Than a 5-Day Schedule in Older...
For older patients with treatment-naïve acute myeloid leukemia (AML), research has suggested that a 10-day treatment schedule of the hypomethylating agent decitabine is associated...
Enasidenib Induces Molecular Remissions in IDH2-Mutated, Relapsed/Refractory AML
A first-in-human trial of patients with relapsed and/or refractory, IDH2-mutated acute myeloid leukemia (AML) found that the IDH2 inhibitor enasidenib was an effective salvage...
FDA Approves Gilteritinib for FLT3-Mutated AML
The oral FLT3/AXL inhibitor gilteritinib was approved by the FDA for the treatment of adult patients with FLT3-mutated, relapsed or refractory AML. The FDA...
FDA Approves Frontline Venetoclax for AML
The BCL2 inhibitor venetoclax, in combination with azacitidine or decitabine or low-dose cytarabine, was approved by the FDA for the treatment of patients with...
Glasdegib Receives Approval for Older Patients With AML
The FDA approved glasdegib, in combination with low-dose cytarabine, for patients with newly diagnosed AML who are aged 75 years or older or who...
First-in-Human Trial Shows AMG 330 Is Tolerable in Relapsed/Refractory AML
AMG 330, an anti-CD33 bispecific T-cell engager (BiTE®) antibody construct, was generally tolerable and demonstrated anti-leukemic activity in patients with relapsed/refractory acute myeloid leukemia...
Early-Phase Trial Shows Venetoclax Plus HMA Has High Response Rates in Older Patients With...
In a phase Ib dose-escalation and dose-expansion study published in Blood, two-thirds of older patients with acute myeloid leukemia (AML) responded to the combination...
Higher Childhood Leukemia Risk in Offspring Raises Questions About Hormonal Contraceptive Safety
Children born to women who were using hormonal contraception within three months of pregnancy and during pregnancy have a higher risk of developing myeloid...
Next-Generation Sequencing MRD Assessment Valuable Tool in AML Management
Assessing minimal residual disease (MRD) using next-generation sequencing (NGS) in patients with acute myeloid leukemia (AML) prior to undergoing allogeneic hematopoietic cell transplantation (alloHCT)...
Demystifying Epigenetics in Hematology
In the early 20th century, German researcher Theodor Boveri described the basic tenets of tumor biology: Cells can turn cancerous when they lose the...
Current Issue
Mid-January 2021 Annual Meeting Edition
This issue features highlights from the 2020 ASH Annual Meeting, a look at doctor-patient gifting customs around the world, and more.